Audentes Set To Resume XLMTM Trial As US Hold Lifts
Talks With Regulators On Way Forward
Executive Summary
Trial of high-need gene therapy set to restart following the deaths of several participants and the lifting of a clinical hold imposed by the US FDA last year.
You may also be interested in...
Next-Gen Gene Therapy Firm Kate Therapeutics Starts Out With Big Pharma Partner
Kate is focused on delivering gene therapies for two rare, neuromuscular diseases by deploying AAV technology that it says will target muscle tissue and enable regulated therapeutic payloads.
Astellas Pauses XLMTM Gene Therapy Trial After Another Safety Scare
The day before an FDA advisory committee meeting about the safety of AAV vector-based gene therapies, Astellas reported liver damage in a patient in its trial of AT132.
Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology
Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.